- Software - Application
- Technology
-
2.46
EPS
-
70.27
P/E
-
20.8B
MARKET CAP
-
0.00%
DIV YIELD
Company Overview
121 SEAPORT BOULEVARD,BOSTON MA 02210,7813705000
CEO
Mr. Neil Barua
Employess
7452
Sector
Technology
Industry
Software - Application
Website
https://www.ptc.com
PTC Inc. operates as software and services company in the Americas, Europe, and the Asia Pacific. The company operates in two segments, Software Products and Professional Services. It offers ThingWorx platform, which offers a set of capabilities that enable enterprises to digitally transform every aspect of their business with innovative solutions that are simple to create, easy to implement, scalable to meet future needs, and designed to enable customers to accelerate time to value; and Vuforia, which enables the visualization of digital information in a physical context and the creation of AR. The company also provides Onshape, a software-as-a-service product development platform unites computer-aided design with data management, collaboration tools, and real-time analytics; Arena, a PLM solution enables product teams to collaborate virtually anytime and anywhere; Creo, a 3D CAD technology enables the digital design, testing, and modification of product models; and Windchill, a product lifecycle management software. In addition, it offers Integrity, an application lifecycle management solution; Servigistics, service parts management solution; and consulting, implementation, training, cloud, and license and support services. The company was formerly known as Parametric Technology Corporation and changed its name to PTC Inc. in January 2013. PTC Inc. was incorporated in 1985 and is headquartered in Boston, Massachusetts.
Next Earnings Date
Nov. 6, 2024
Ex Dividends date
--
Dividend Date
--
YTD Performance
2.68%
Fiscal Year End
09-30
IPO Date
1989-12-08
Growth Rates
| (avg. rate of change) | 10 years | 5 years | 3 years | 1 year |
|---|---|---|---|---|
| Sales/Revenue | 4.95% | 11.05% | 12.87% | 8.47% |
| EPS | 5.69% | 35.69% | 22.36% | -22.47% |
| Equity | 11.20% | 25.08% | 23.01% | 16.60% |
| Cash | 1.76% | 2.08% | 1.51% | 5.85% |
| Return On Capital (ROIC) | 4.04% | 5.64% | 9.67% | 7.40% |
Debt
| year (millions) | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Short Term Debt | 9.38 | 22 | 27.9 | 34.6 | 0.0 |
| Long Term Debt | 1,890 | 1,540 | 1,650 | 1,190 | 669 |
| LT Finance Leases | 193 | 190 | 209 | 215 | 0.0 |
| Shares Outstanding | 118 | 117 | 117 | 116 | 118 |
| Market Cap | 16,800 | 12,300 | 14,000 | 9,570 | 8,030 |
Price
News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
1 monthNEW YORK, NY / ACCESSWIRE / August 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
accesswire.com
1 Magnificent Software Stock Down 10% to Buy and Hold Forever
1 monthThe annual run rate of recurring revenue continues to grow at a double-digit rate. Free cash flow is growing more than recurring revenue growth.
fool.com
The 3 Best Augmented Reality Stocks to Buy in August 2024
1 monthAs we advance further into the digital age, augmented reality (AR) continues to emerge as a pivotal technology reshaping numerous industries. The AR market is ripe for significant growth.
investorplace.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
1 monthNEW YORK , Aug. 9, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
prnewswire.com
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
1 month– Continued strong revenue performance – – NDAs for sepiapterin and Translarna™ submitted to FDA – – Positive interim data readout from PTC518 PIVOT-HD study – – On track to achieve remaining 2024 clinical and regulatory milestones – WARREN, N.J. , Aug. 8, 2024 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ending June 30, 2024.
prnewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
1 monthNEW YORK, NY / ACCESSWIRE / August 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
accesswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
2 monthsNEW YORK, Aug. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
globenewswire.com
PTC Inc. (PTC) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
2 monthsWhile the top- and bottom-line numbers for PTC Inc. (PTC) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zacks.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
2 monthsNEW YORK , Aug. 1, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
prnewswire.com
PTC's Q3 Earnings Match Estimates, Revenues Decrease Y/Y
2 monthsPTC Inc. PTC reported third-quarter fiscal 2024 non-GAAP earnings per share (EPS) of 98 cents, down 1% on a year-over-year basis. The figure came in line with the Zacks Consensus Estimate.
zacks.com
PTC Inc. (PTC) Q3 2024 Earnings Call Transcript
2 monthsPTC Inc. (NASDAQ:PTC ) Q3 2024 Results Earnings Conference Call July 31, 2024 5:00 PM ET Company Participants Matt Shimao - Head of Investor Relations Neil Barua - Chief Executive Officer Kristian Talvitie - Executive Vice President and Chief Financial Officer Conference Call Participants Siti Panigrahi - Mizuho Securities Tyler Radke - Citigroup Joe Vruwink - Robert W. Baird Stephen Tusa - J.P.
seekingalpha.com
PTC Inc. (PTC) Q3 Earnings Meet Estimates
2 monthsPTC Inc. (PTC) came out with quarterly earnings of $0.98 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.99 per share a year ago.
zacks.com